BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$9.31

Market cap

$2.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.73

Enterprise value

$3.05B

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 46
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 18

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights
Biocryst Pharmaceuticals's gross profit has soared by 77% YoY
BCRX's revenue has soared by 76% YoY
BCRX's debt has soared by 80% QoQ and by 3.5% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 36% YoY and by 9% QoQ

Key stats

What are the main financial stats of BCRX

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
1.86%
1 week
4.37%
1 month
12.3%
1 year
-6.05%
YTD
19.36%
QTD
-2.21%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$885.72M
Gross profit
$865.83M
Operating income
-$381.84M
Net income
-$457.98M
Gross margin
97.8%
Net margin
-51.7%
Biocryst Pharmaceuticals's gross profit has soared by 77% YoY
BCRX's revenue has soared by 76% YoY

Price vs fundamentals

How does BCRX's price correlate with its fundamentals

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.45
BCRX's equity is down by 23% year-on-year
BCRX's revenue has soared by 76% YoY
The P/S is 69% lower than the 5-year quarterly average of 8.1

Efficiency

How efficient is Biocryst Pharmaceuticals business performance

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 54% lower than its total liabilities
The total liabilities has soared by 61% from the previous quarter and by 9% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 36% YoY and by 9% QoQ
BCRX's debt has soared by 80% QoQ and by 3.5% YoY
BCRX's debt to equity has surged by 61% since the previous quarter and by 16% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.